2 ). Then, all samples were pulsed with EdU (10μM) for 30min, stained for γH2AX and analyzed by FACS for EdU incorporation (A) and γH2AX-intensity (B). A minimum of 200 random cells was analyzed per sample. Kurskal-Wallis test (**** = p<0.0001 and ns = not significant). (C) Analysis of replication fork progression by DNA fiber spreading in the presence or absence of an ICL treatment. U2OS cells were incubated in the presence or absence of DIG-TMP (5μM), TMP (30nM) for 1h, followed by UVA (0.3J/cm 2 ; 3J/cm 2 ) irradiation. Cells were then provided with chlorodeoxyuridine (CldU, 30μM, red) . 25 min later, cells were washed and supplemented with iododeoxyuridine (IdU, 250μM, green) . For MMC (200nM) treatment; MMC was added along with CldU and IdU. Replication tract lengths (red + green) were measured for the tracts. A minimum of 100 tracts were analyzed per sample. Kurskal-Wallis test (**** = p<0.0001, *** = p<0.001). (D-E) U2OS cells were transfected with siLuc or siFANCD2 for 48h. Following transfection, cells were either left untreated or treated with TMP (30nM) and UVA (0.3J/cm 2 ). Post irradiation cells were collected at the indicated time points for cell cycle and DDR analysis via FACS. Cell cycle analysis was performed using DAPI staining (D). γH2AX intensities for 400 random cells was extracted and plotted to determine the DDR response. (B) Representative images of DNA fibers generated as described in Figure 2B . Magenta arrows, local fibers (encountering an ICL (DIG-label) during nucleotide analogue incorporation). White arrows, global fibers (fibers without a DIG label, hence no ICL). (C) Relative proportion (%) of DNA fibers that contain a DIG-label (+, local forks) and fibers that are label-free (-, global forks), within the CldU/IdU-labelled track. U2OS cells optionally treated for 1h with DIG-TMP  (5μM) + UVA (3J/cm 2 ), Olaparib (10μM) or in combination, and processed for nucleotide analogue incorporation as described in Figure 2B . A minimum of 100 tracts were analyzed per sample. Kurskal-Wallis test (**** = p<0.0001 and ns = not significant). (B) Quantification of the olive tail moment as assessed by the open comet plugin of ImageJ in neutral comet assay: RPE-1 cells were transfected either with siLuc or siRAD51 and 24h later, and were then either left untreated or treated with TMP (30nM) and UVA (300mJ/cm 2 ). Cells were collected 1 hour post irradiation. Neutral comet assay was performed. (C) U2OS cells were transfected either with siLuc or siRAD51 (second oligo siRAD51_F2) and 24h later, cells were either left untreated or treated with TMP (30nM) and UVA (300mJ/cm 2 ). Cells were collected 1 hour post irradiation. Neutral comet assay was performed. (top) Western blot analysis showing down regulation of RAD51 with two different oligonucleotides. At least 50 comets were scored per sample. Kurskal-Wallis test (**** = p<0.0001, ** p <0.01 and ns = not significant). (D) SLX4 protein expression levels were analyzed by western blot analysis of total cell extracts from the FIT inducible SLX4 WT and FLW cell lines in the experimental conditions of Figure 4E . GAPDH, loading control. (E) SLX4 and RAD51 protein expression levels were analyzed by western blot analysis of total cell extracts from the FIT inducible SLX4 cell line in the experimental conditions given in Figure 4F . TFIIH, loading control. (F) ZRANB3, MUS81 and FANCD2 protein levels analysed by western blot of total cell extracts from ZRANB3 wild type and ZRANB3 knockout cells (related to figure 4G ). α-tubulin, loading control. (G) Frequency of local replication patterns as detected by DNA fibers (as in fig 5A) in NEIL3 proficient and NEIL3 deficient MEFs. A minimum of 100 replication forks were analyzed per sample. (H) Western blot analysis of total cell extracts from cells of the DNA fiber analysis (left) to assess the downregulation of FANCM protein levels and the phosphorylation status of CHK1 over total CHK1 protein. GAPDH, loading control (related to figure 5E ). (I) Global rate of fork progression was assessed in DNA fiber spreading assay as depicted in Figure 2B in U2OS cells which have priorly been transfected with siRNA directed against Luciferase (siLuc, control) and FANCM (siFANCM). A minimum of 100 fibers was analyzed per sample. Kurskal-Wallis test (**** = p<0.0001 and ns = not significant). . (C-E) U2OS cells were incubated for 30min with or without DIG-TMP (5μM), AZ20 (ATR inhibitor, 1μM) and CDC7i (XL413, 10μM) in indicated combinations. Then, cells were irradiated with UVA (3J/cm 2 ) and EdU (10μM) incorporation was allowed for 30min in the presence or absence of AZ20 (ATR inhibitor, 1μM) and CDC7i (XL413, 10μM). Immunofluorescence was performed against DIG and γH2AX. DIG and γH2AX have been plotted respectively (D-E) for 100 cells. (F-G) EdU incorporation and γH2AX assessed by FACS analysis: U2OS cells were incubated for 30min with or without TMP (30nM), VE821 (ATR inhibitor, 1μM), CDC7i (XL413, 10μM) or in all possible combination of the three. Then, cells were irradiated with UVA (300mJ/cm 2 ) and EdU (10μM) incorporation was allowed for 30min in the presence or absence of AZ20 (ATR inhibitor, 1μM), CDC7i (XL413, 10μM) or both. EdU intensity and γH2AX values in S-Phase cells were extracted for a minimum of 400 random cells per sample. Kurskal-Wallis test (**** = p<0.0001 and ns = not significant). (H) Working model for how global fork slowing and reversal assists ICL traverse and prevents DSB formation. While some forks directly approach ICLs, ssDNA accumulation triggers local ATR activation (I), which then extends to chromosomal regions not directly challenged by ICLs (II). Extensive fork reversal enables global fork slowing providing more time for ICL repair on the template and promoting slow, single-fork approach to ICLs (III). Once a fork has reached an ICL, fork remodeling may also directly assist retuning of the replisome, to allow -by yet-elusive mechanisms -ICL bypass and template unwinding beyond the lesion (IV). Efficient ICL traverse allows repairing residual ICLs post-replicatively (V-VI), minimizing the risk of incision-dependent breaks at replication forks (VII-VIII). Figure 3C . (C) Percentage of observed reversed forks (% RF) in two independent EM experiments for samples in Figure 3D . (D) Percentage of observed reversed forks (% RF) in two independent EM experiments for samples in Figure 3E . Number of analyzed molecules is indicated in brackets. Table S2 . Electron microscopy data for Figure 5E . Percentage of observed reversed forks (% RF) in two independent EM experiments for samples in Figure 5E . Number of analyzed molecules is indicated in brackets. Table S3 . Electron microscopy data for Figure 6B . Percentage of observed reversed forks (% RF) in two independent EM experiments for samples in Figure 6B . Number of analyzed molecules is indicated in brackets. Table S4 . Electron microscopy data for Figure 6E . The top four rows indicate the absolute number of postreplicative junctions (PRJ, see Figure 6C ) and X-shaped molecules (X, see Figure 6D ) observed in two independent EM experiments, for the samples included in Figure 6E . The total number of molecules analyzed in each experiment is indicated in brackets. The bottom two rows indicate cumulative number and frequency (%) of PRJ-and X-molecules, pooling the data of the two independent experiments, which showed similar trends of accumulation of these intermediates. These cumulative values (bold) are represented graphically in Figure 6E . Table S5 . Electron microscopy data for Figure 6F . The top four rows indicate the absolute number of postreplicative junctions (PRJ, see Figure 6C ) and X-shaped molecules (X, see Figure 6D ) observed in two independent EM experiments. The total number of molecules analyzed in each experiment is indicated in brackets. The bottom two rows indicate cumulative number and frequency (%) of PRJ and X-molecules, pooling the data of the two independent experiments, which showed similar trends of accumulation of these intermediates. These cumulative values (bold, Xs + PRJs) are represented graphically in Figure 6F . Table S6 . Electron microscopy data for Figure 6G . The top four rows indicate the absolute number of postreplicative junctions (PRJ, see Figure 6C ) and X-shaped molecules (X, see Figure 6D ) observed in two independent EM experiments. The total number of molecules analyzed in each experiment is indicated in brackets. The bottom two rows indicate cumulative number and frequency (%) of PRJ and X-molecules, pooling the data of the two independent experiments, which showed similar trends of accumulation of these intermediates. These cumulative values (bold, Xs + PRJs) are represented graphically in Figure 6G . Figure 7G. (B) Percentage of observed reversed forks (% RF) in two independent EM experiments for samples in Figure 7H . Number of analyzed molecules is indicated in brackets.
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Methods S1: Refined synthesis of DIG-TMP
Materials: All chemicals were of reagent grade quality or better, obtained from commercial suppliers and used without further purification. Solvents were used as received or distilled using standard procedures. All preparations were carried out using standard Schlenk techniques. Thin layer chromatography (TLC) was performed using silica gel 60 F-254 (Merck) plates with detection of spots achieved by exposure to UV light. Column chromatography was performed using Silica gel 60 (0.040-0.063 mm mesh, Merck). Eluent mixtures are expressed as volume to volume (v/v) ratios.
1) Instrumentation and methods
NMR spectra were recorded in deuterated solvents on a Bruker 400 MHz spectrometer at room temperature. The chemical shifts, δ, are reported in ppm (parts per million). The signals from the residual protons of deuterated solvent have been used as an internal reference. The abbreviations for the peak multiplicities are as follows: s (singlet), d (doublet), dd (doublet of doublets), t (triplet), q (quartet), m (multiplet), and br (broad). UPLC-ESI-MS was performed by a UPLC system (Acquity Ultra Performance LC, Waters) that was connected to a mass spectrometer (Bruker Esquire 6000) operated in ESI mode. A reverse phase Acquity UPLC BEH C18 (2.1 ´ 50 mm) column was used at a flow rate of 0.5 mL min -1 . The UV absorption was measured at 254 nm. The runs were performed with a linear gradient of A (acetonitrile (Sigma-Aldrich HPLC grade) and B (distilled water containing 0.1% HCOOH): t = 0 -0.5 min, 5% A; t = 4 -5 min, 100% A. ESI mass spectrometry was performed using a Bruker Esquire 6000 spectrometer. In the assignment of the mass spectra, the most intense peak is listed. High-resolution mass spectrometry were performed on a Bruker ESQUIRE-LC quadrupole ion trap instrument (Bruker Daltonik GmbH, Bremen, Germany), equipped with a combined Hewlett-Packard Atmospheric Pressure Ion (API) source (Hewlett-Packard Co., Palo Alto, CA, USA). The solutions (about 0.1-1 µmol/ml) were continuously introduced through the electrospray interface with a syringe infusion pump (Cole-Parmer 74900-05, ColeParmer Instrument Company, Vernon Hills, Illinois, USA) at a flow rate of 5 µl min -1 . The MS conditions were: Nebulizer gas (N 2 ) 15 psi, dry gas (N 2 ) 7 min -1 , dry temperature 300°C, capillary voltage 4000 V, end plate 3500 V, capillary exit 100 V, skimmer1 30 V, and trap drive 70. The MS acquisitions were performed at normal resolution (0.6 u at half peak height), under ion charge control (ICC) conditions (10'000) in the mass range from m/z 100 to 2000. To obtain representative mass spectra, 8 scans were averaged. 
2) Synthesis of compounds.
Compound 2. (Braun et al., 2004) 1-N-Boc-1,13-diamino-4,7,10-trioxatridecane (2) was synthesized following an adapted procedure by Braun et al. (Braun et al., 2004) Under N 2 atmosphere, 4,7,10-trioxa-1,13-tridecanediamine, 1 (3.00 g, 13.62 mmol) was dissolved in dry 1,4-dioxane (30 mL). Meanwhile, a solution of di-tert-butyl dicarbonate (0.59 g, 2.72 mmol) was prepared in dry 1,4-dioxane (20 mL). 
dicarbonate was then added slowly (ca. 5 min) to the solution of 1. The cloudy reaction mixture was allowed to stir at room temperature for 26 h before solvent was evaporated. The residue was dissolved in CH 2 Cl 2 (100 mL), was washed with H 2 O (3 x 100 mL). The organic layer was dried over MgSO 4 , filtered and the solvent was evaporated to obtain 2 as colourless oil. Yield: 99% (0.867 g, 2.71 mmol). The spectroscopic data matched those reported previously (Braun et al., 2004) .
Compound 3. (Isaacs et al., 1977) The compound was synthesized following a procedure reported by Isaacs et al. (Isaacs et al., 1977) . Briefly, glacial acetic acid (200 mL) was added to trioxsalen (1.50 g, 6.58 mmol) under N 2 atmosphere). The colourless suspension was gently heated up to 70 °C until trioxsalen was fully dissolved. After allowing the reaction to reach room temperature, chloromethyl methyl ether (8 mL) was added and the reaction solution was allowed to stir at room temperature overnight. After 27 h a second portion of chloromethyl methyl ether (16 mL) was added and the reaction was stirred for additional 24 h. After a total reaction time of 51 h, 2/3 of the glacial acetic acid was evaporated and the remaining residue was placed in the fridge until a colourless precipitated was formed. The precipitate was collected and washed with ethyl acetate (20 mL). The precipitate was resuspended in 20 mL ethyl acetate, briefly sonicated and centrifuged (the washing procedure was repeated two times). The solid obtained was dried using high vacuum to afford 3 as off-white powder. Yield: 66% (1.2 g, 4.34 mmol). The crude material was directly used for the next step without further purification.
Compound 4.
A mixture of compound 3 (0.5 g, 1.8 mmol) and 2 (1 g, 3.1 mmol) in dry toluene (50 mL) was heated at 120 °C for 15 h under N 2 atmosphere. The solvent was removed using rotary evaporator. The residue was loaded on a silica column and eluted using DCM:MeOH 12:1. The fractions containing the product were collected and solvent was removed, dried in high vacuum. To a stirred solution of 4 (0.084 g, 0.15 mmol) in 2 mL DCM on an ice bath, 1 mL TFA was added under N 2 atmosphere. The reaction mixture was stirred for 30 min at 0°C and then 2 h at room temperature before the solvent was removed. The resulting yellow oil was dissolved in 1 mL of DMF and 42 µL of NEt 3. Dig-NHS (0.035 g, 0.052 mmol) was then added to the solution. The reaction mixture was stirred at room temperature for 12 h under N 2 atmosphere. The solvent was removed using a high vacuum pump and the residue was purified my silica column chromatography using DCM:MeOH 6:1 as eluent. The fractions containing the compound was collected and the solvent was removed using a rotary evaporator. 
